Tarsus Pharmaceuticals: iRenix Medical acquisition adds complementary pipeline asset; Buy

Research evidence excerpt

Tarsus Pharmaceuticals: iRenix Medical acquisition adds complementary pipeline asset; Buy

Accessible version

Tarsus Pharmaceuticals

iRenix Medical acquisition adds

complementary pipeline asset; Buy

Maintain Rating: BUY | PO: 89.00 USD | Price: 67.73 USD

IRX-101 adds to TARS ophthalmic pipeline 08 July 2026

Today, TARS announced the acquisition of iRenix Medical and their asset IRX-101, a Equity

Ph2/3 ocular antiseptic. On the surface, IRX-10 looks like niche peak sales drug based on

Jason M. Gerberry

size of upfront cost ($75m) and genericized end-market. The asset looks complementary Research Analyst

to the TARS business, as it can be promoted by a more targeted field force (expected to BofAS jason.gerberry@bofa.com

be less than half the size of Xdemvy’s), and has a clearly established and partly de-risked

Melanie Fong

profile intended for a large market. Key next steps for IRX-101 are to finish Ph3 Research Analyst

(initiation planned for 1H27), which will include a safety trial and in-vitro antimicrobial BofAS melanie.fong@bofa.com

study, positioning the asset for 2029 time-to-market. The drug has completed a Ph2/3

Chi M. Fong

demonstrating head-to-head stat sig benefit on pain and corneal staining (measure of Research Analyst

corneal damage) endpoints vs. betadine. The market is comprised of ~11m US BofASchi.fong@bofa.com

intravitreal injection procedures requiring a pre-emptive antiseptic installation. Tarsus Dina Ramadane

looks to differentiate from betadine (current market standard) on patient tolerability and Research Analyst

minimizing corneal toxicity (surface damage) – on the conference call, mgmt indicated it BofASdina.ramadane@bofa.com

believes differentiation can translate to value but refrained from commenting on pricing. Richard Wagner >>